<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
MGC Pharmaceuticals Ltd (ASX:MXC, LON:MXC) hailed as a “major milestone” the recruitment of its first patient to a phase III trial of its cannabis-derived drug in patients hospitalised with Covid. In all, 252 people will take part in the double-blind, placebo-controlled efficacy and safety evaluation of CimetrA following initial dosing at the Rambam Medical Center in Israel.
...read full article on Proactive Investors
